White House launches direct to consumer drug site
U.S. President Donald Trump makes an announcement from the Oval Office at the White House in Washington, DC, on November 6, 2025.
Jonathan Ernst | Reuters
President Donald Trump on Thursday will announce the launch of TrumpRx, a direct-to-consumer website that is key to his administration’s efforts to lower prescription drug costs in the United States.
Inside a post on xWhite House press secretary Karoline Leavitt said Trump and other administration officials will unveil the new website at 7 p.m. ET on Thursday.
He said millions of Americans will save money through TrumpRx, but it’s not yet clear whether all patients, especially those with insurance coverage, will see greater cost savings in using the site to buy their medications. TrumpRx targets people willing to pay cash and forego insurance; This suggests that people with no or limited insurance coverage may benefit the most.
The site is not expected to sell drugs directly to American patients, but will serve as a central hub directing them to drug manufacturers offering discounts on certain products on their direct-to-consumer sites. For example, Eli Lilly And Novo Nordisk They offered blockbuster obesity drugs at deep discounts to patients who paid with cash.
In recent months, both companies and at least 14 other drugmakers have signed deals with the Trump administration to join the platform and voluntarily sell some drugs at a discount to Medicaid patients. These landmark agreements are part of Trump’s broader “most favored nation” policy, which seeks to tie U.S. drug prices to the lowest prices abroad.
This is the government’s latest effort to rein in U.S. prescription drug prices. on average two to three times higher in other developed countries and up to 10 times more than in certain countries, according to Rand Corp., a public policy think tank.
In an exclusive interview with CNBC last week, Eli Lilly CEO Dave Ricks said the company was the first drugmaker to sell obesity treatments directly to patients and that TrumpRx is “taking that and expanding it to other drugs across the industry.”
“This is what we’re all for,” Ricks said.
Questions about savings
Questions remain about how much savings people can expect if they use TrumpRx to purchase their medications.
Price reductions announced for some drugs are framed as steep reductions from so-called retail list prices. For example, under Novo Nordisk’s agreement with management, diabetes drug Ozempic will be priced at $350 per month on TrumpRx; That’s less than half the monthly list price of about $1,000.
But these list prices are often much higher than what private insurance companies and government programs pay for the drugs after discounts, rebates, and other concessions. Researchers at the Georgetown Medicare Policy Initiative. This suggests that some payers may already be securing prices comparable to or lower than the newly announced discounts on drugs under the Trump deals.
researchers I quoted from a study It found that average discounts on brand-name drugs in Medicare Part D account for about 40% of list prices. Meanwhile, discounts on Medicaid exceed 75 percent Congressional Budget Office study.
